Healthcare Global Enterprises Limited has announced a significant fundraising plan through a rights issue, giving existing shareholders an opportunity to increase their stake in the company at a predetermined price. The board had earlier approved the proposal in its February 17, 2026 meeting, and the detailed terms were subsequently finalized on February 24, 2026.
Under this rights issue, the company plans to raise up to ₹42,500 lakh by issuing fully paid-up equity shares with a face value of ₹10 each. The total issue size stands at 82,94,566 rights equity shares, aggregating to approximately ₹42,468.18 lakh, assuming full subscription.
The rights issue price is ₹512 per share, which includes a premium of ₹502 over the face value. In simple terms, investors will pay ₹10 as face value and ₹502 as premium for each rights share they subscribe to. These rights entitlements (REs) will be credited to eligible shareholders’ demat accounts under the specified ISIN before the issue opens, allowing them either to apply for shares or renounce (sell) their entitlements.
Looking at the timeline, the last date for credit of rights entitlements is March 4, 2026, meaning eligible shareholders should see the REs in their demat accounts by this date. The issue opens on March 11, 2026, from which investors can begin applying for the rights shares or trade their REs on the exchange. Shareholders who prefer to sell their entitlements must do so by the last date for on-market renunciation, March 20, 2026.
The rights issue will close on March 25, 2026, which is the final deadline to submit applications. After the issue closes, the company will determine the allocation. The basis of allotment will be finalized on March 27, 2026, and the formal date of allotment is also March 27, 2026.
Successful applicants can expect the rights equity shares to be credited to their demat accounts on March 30, 2026. Following this, the newly issued shares are scheduled to list on the stock exchanges on April 1, 2026, after which they will trade like regular equity shares.
Overall, this rights issue provides existing shareholders of Healthcare Global Enterprises a structured opportunity to participate in the company’s capital raise. Investors should carefully evaluate the pricing, their entitlement ratio, and the company’s fundamentals before deciding whether to subscribe, renounce, or ignore the offer.
Over the past three years, Healthcare Global Enterprises has reported weak net cash flow, primarily because of sustained outflows under investing activities. While operating cash flow has remained healthy and steadily improved, the company has been deploying significant capital into expansion and capacity building. This aggressive investment phase has kept the overall net cash flow under pressure, which naturally increases the need for external fund raising, such as the current rights issue, to support growth without overburdening the balance sheet.
On the earnings side, the company has demonstrated strong and consistent sales growth over the years, reflecting robust demand and business expansion. However, this revenue momentum has not fully translated into proportional profit growth. The key drag factors are the elevated interest costs and rising depreciation charges, which indicate higher debt levels and ongoing capital expenditure. As a result, net profit has remained relatively muted despite healthy operating performance. This financial pattern suggests the company is in an investment-heavy phase where near-term profitability is compressed while building assets for future growth.
Q1: What is the total amount Healthcare Global Enterprises aims to raise through this rights issue, and how many shares will be issued? A1: The company aims to raise up to ₹42,500 lakh by issuing 82,94,566 fully paid-up equity shares, with the actual amount aggregating to approximately ₹42,468.18 lakh assuming full subscription.
Q2: What is the rights issue price per share, and how is it structured in terms of face value and premium? A2: The rights issue price is ₹512 per share, comprising a face value of ₹10 and a premium of ₹502 per share.
Q3: What options are available to eligible shareholders once rights entitlements (REs) are credited to their demat accounts? A3: Eligible shareholders can either apply for the rights shares (subscribe), trade or sell their entitlements on the exchange (renounce), or choose to do neither and ignore the offer entirely.
Q4: What is the last date for on-market renunciation, and why is this deadline significant? A4: The last date for on-market renunciation is March 20, 2026. It is significant because shareholders who wish to sell their entitlements rather than subscribe must complete the transaction by this date, after which they can no longer trade the REs on the exchange.
Q5: What is the complete timeline from allotment to listing for this rights issue? A5: The basis of allotment and formal date of allotment are both March 27, 2026. Rights equity shares will be credited to successful applicants’ demat accounts on March 30, 2026, and the shares are scheduled to list on stock exchanges on April 1, 2026.
Q6: Why has the company’s overall net cash flow remained weak despite healthy operating cash flow? A6: The weak net cash flow is primarily due to sustained and significant outflows under investing activities, as the company has been deploying large amounts of capital into expansion and capacity building, which offsets the positive operating cash flow.